Pfizer league of Top3 for cancer therapy by 2018

According to WHO report cancer will lead to death of more than 11.4 million people globally by year 2030 and some market reports state that revenue in this segment has crossed over to 11% from previous year which is worth $50 Billion.

At present Roche is market leader for cancer treatment globally, with a market share of 34.9% (equivalent to $13 Billion sales) in 2007, some other major players include Amgen, Sanofi-Aventis, Merck KgaA, Novartis, Schering-Plough and Eli Lilly.


Currently Pfizer is ranked in seventh position in cancer drug segment with annual sales of around $2.5 Billion, According to some sources it is said that Pfizer is planning to position itself in Top 3 by year 2018 as from some years Pfizer has started spending around 20 per cent of its annual research budget for developing novel cancer therapies and now it has around 20+ drugs in its cancer treatment pipeline out of which 8 are in Phase II clinical trials and 13 in Phase I clinical trials.